PJT Partners stock fell 1.46% on Wednesday following downbeat analyst moves. Keefe, Bruyette & Woods downgraded the stock to market perform from outperform with a price target cut from $195 to $159, citing concerns about slowing M&A growth. UBS also reduced its price target from $176 to $165. The declines reflect worries that rising interest rates are making companies more hesitant to pursue debt-funded deals, pressuring the boutique investment bank's advisory business.

Houlihan Lokey reports rising private credit stress concentrated among smaller borrowers, with sub-$100M EBITDA companies posting 3% default rates by loan value. The $10M-$20M EBITDA segment shows the most weakness, with 12% of loans trading below 90% of par versus 1% in 2023. Larger borrowers remain healthier, and overall fundamentals remain supportive with median revenue growth of 6.5% and EBITDA growth of 7.4%.

Houlihan Lokey (HLI) shares have declined 21.3% year-to-date due to two disappointing quarters, a 24% revenue drop in Corporate Finance, and a 54% decline in technology-related revenues. While the company maintains record backlog and a diversified business model, earnings estimates remain under pressure with a consensus decline of 8.3% expected. Analysts recommend avoiding the stock until operating trends stabilize.

PJT Partners' General Counsel David Travin sold 3,000 shares (~$457K) in May 2026, reducing his direct holdings by 59.38%. The article argues this insider sale is routine compensation management and not indicative of conviction in the stock. The real metric to watch for PJT is deal flow and transaction volume, as the independent investment bank's earnings are tied to deal cycles rather than predictable schedules.

PJT Partners reported record Q2 2025 financial results, with GAAP revenue of $406.9 million (up 13% year-over-year) and adjusted EPS of $1.54, beating analyst expectations. Strategic advisory services drove performance, offsetting declines in placement fees.

PJT Partners (PJT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

PJT Partners (PJT) possesses solid growth attributes, which could help it handily outperform the market.

Blue Owl Capital Corporation (OBDC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

PJT Partners (PJT) possesses solid growth attributes, which could help it handily outperform the market.

PJT Partners (PJT) delivered earnings and revenue surprises of 117.78% and 44.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Ratings for PJT Partners (NYSE:PJT) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1 1 Last 30D 0 0 0 0 1 1M Ago 0 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 2 1 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $94.6, a high estimate of $110.00, and a low estimate of $75.00. This current average represents a 5.16% decrease from the previous average price target of $99.75. Interpreting Analyst Ratings: A Closer Look In examining recent analyst actions, we gain insights into how financial experts perceive PJT Partners. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Brennan Hawken UBS Lowers Sell $75.00 $100.00 Devin Ryan JMP Securities Raises Market Outperform $110.00 $105.00 Brennan Hawken UBS Raises Neutral $100.00 $86.00 James Yaro Goldman Sachs Lowers Neutral $99.00 $108.00 Steven Chubak Wolfe Research Announces Underperform $89.00 - Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to PJT Partners. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to ...Full story available on Benzinga.com

Throughout the last three months, 5 analysts have evaluated PJT Partners (NYSE:PJT), offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 2 1 0 Last 30D 0 1 0 0 0 1M Ago 0 0 2 0 0 2M Ago 1 0 0 1 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for PJT Partners, revealing an average target of $101.2, a high estimate of $110.00, and a low estimate of $89.00. This upward trend is evident, with the current average reflecting a 2.48% increase from the previous average price target of $98.75. Analyzing Analyst Ratings: A Detailed Breakdown The analysis of recent analyst actions sheds light on the perception of PJT Partners by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Devin Ryan JMP Securities Raises Market Outperform $110.00 $105.00 Brennan Hawken UBS Raises Neutral $100.00 $86.00 James Yaro Goldman Sachs Lowers Neutral $99.00 $108.00 Steven Chubak Wolfe Research Announces Underperform $89.00 - Richard Ramsden Goldman Sachs Raises Buy $108.00 $96.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PJT ...Full story available on Benzinga.com